Baxter Healthcare Corporation reported early progress using mouse models in the development of a longer-acting therapy for hemophilia A. Preclinical data drawn from ongoing research indicate that the half-life of recombinant factor VIII may be extended when it is formulated with recombinant von Willebrand factor. The data were presented at the American Society of Hematology’s 48th Annual Meeting December 9-12, 2006 in Orlando, FL.
The benefit of new factor therapies with an improved half-life is that they would remain active in the body for longer periods, resulting in the need for fewer infusions. Baxter will continue preclinical research until the experimental therapy is ready for clinical studies in patients.
“We continue to build upon our proven foundation of blood-free recombinant protein processing with the goal of developing recombinant proteins with a longer half-life, which if supported by future clinical trial results, potentially allow for less frequent injections and therefore increase convenience and compliance for patients,” said Peter Turecek, PhD, Senior Director of Preclinical Research and Development for Baxter BioScience.
Source: Baxter Healthcare Corporation news release dated December 11, 2006